CARIS LIFE SCIENCES INC (CAI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$25.07-0.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Caris Life Sciences aims for $1.0B to $1.02B revenue in 2026. Clinical therapy volume should grow about 20% this year. The company has beaten earnings several times recently. Profitability is still weak but management is stable.
The company is still losing money and faces risks from recent credit changes. Revenue growth may slow below targets. The stock has sold off sharply and faces elevated risk.
The price is about 14% below our fair value near $20. Analysts expect 21% revenue growth. Our value is below the Street median, reflecting caution on profitability and risks.
Breaks if: clinical therapy volume growth falls below 15% in 2026
Breaks if: EPS remains negative through 2027
Breaks if: annual revenue falls below $1.0B in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a cyclical play within the healthcare sector. The current thesis state is intact, with recent financial performance remaining strong despite some mixed signals.
The market appears to have priced in a low expectations gap, suggesting that CAI is seen as cheap compared to its peers. However, the valuation reflects a justified stance, indicating that the stock is not overly fragile at this time.
Management is on track to achieve its revenue and volume growth targets, with strong year-over-year growth reported. However, there is a near-term risk of missing earnings expectations, as the company operates in a high-miss-rate industry.
The future performance hinges on sector momentum from key players and whether CAI can maintain its guidance without cuts. Additionally, broader economic indicators, such as job reports, will impact investor sentiment and stock performance.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Yes, our read has weakened. Insider selling by President Spetzler may signal a lack of confidence in future performance. This follows a share repurchase program of up to $100 million, which adds uncertainty.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Caris Life Sciences aims to achieve full year 2026 revenue between $1.0 billion and $1.02 billion.
Overall, CAI's trajectory looks promising, but it must navigate potential risks in the near term. Not investment advice.